Gain Therapeutics

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson's Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson's Disease Models GT-02287 Prevents Tau Accumulation in a Cellular Model BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of new evidence supporting the disease-modifying activity of GT-02287 in preclinical animal models of both GBA-1 and idiopathic Parkinson's disease during a late-breaker poster session yesterday at the Society for Neuroscience (SfN) 2024 conference that is being held October 5-9 in Chicago, IL.

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, interim Chief Executive Officer and current Chief Financial Officer of Gain, will participate in two upcoming investor conferences:

Gain Therapeutics to Participate at Upcoming Investor Conferences

GT-02287 Increases Peripheral GCase Activity GT-02287 Demonstrates CNS Exposure Company to Host Webinar to Discuss Results at 8:30 AM ET Today BETHESDA, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of a late-breaking abstract at the International Congress of Parkinson's Disease and Movement Disorders.

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson's Disease Patients

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced presentations, including two late-breakers, at Neuroscience 2024 featuring preclinical data supporting development of GT-02287, the Company's clinical stage lead drug candidate, in Parkinson's disease with or without a GBA1 mutation. Neuroscience 2024, the Society for Neuroscience's premier event, will be held at McCormick Place Convention Center in Chicago, IL from October 5-9, 2024.

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson's Disease, on Track to Initiate Phase 1b Trial in Patients in Q4 2024 BETHESDA, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces positive results from the Phase 1 study conducted to evaluate the safety, tolerability and pharmacokinetics of GT-02287.

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson's Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the last healthy subject in the multiple ascending dose (MAD) part of its Phase 1 study has completed the highest planned dose levels.

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

Gain Therapeutics, Inc. (NASDAQ:GANX ) Special Call Transcript July 1, 2024 8:30 AM ET Company Participants Apaar Jammu - Manager, Investor Relations Gene Mack - Chief Financial Officer & Interim Chief Executive Officer Conference Call Participants Operator Hello, all. Thank you for joining us today for Gain Therapeutics Corporate and Business Update Call.

Gain Therapeutics, Inc. (GANX) Special Call Transcript

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open.

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Data demonstrates improvement in cognitive function in GBA1 Parkinson's disease model in addition to reversal of motor function deficits Data demonstrates improvement in cognitive function in GBA1 Parkinson's disease model in addition to reversal of motor function deficits

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference taking place June 27, 2024.

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Gain Therapeutics (NASDAQ: GANX ) stock is falling on Friday following the pricing of its shares in a public offering. This public offering has Gain Therapeutics selling 7,116,547 shares and pre-funded warrants for 1,031,602 shares.

Why Is Gain Therapeutics (GANX) Stock Down 25% Today?

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per share and (ii) pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their original issuance. The purchase price of each pre-funded warrant sold in the offering will be equal to the price at which a share of common stock is sold in the offering, minus $0.0001, and the exercise price of each pre-funded warrant will equal $0.0001 per share.

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre-funded warrants offered in the offering. All of the securities are being offered by the Company.

Gain Therapeutics Announces Proposed Public Offering

New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson's disease New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson's disease

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which had already generated a Phase 3 drug in the past, may be overlooked by investors.

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended March 31, 2024, and provides a corporate update.

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Gain Therapeutics (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces positive results from the single ascending dose (SAD) part of its Phase 1 study. GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events. The good safety and tolerability profile and the appropriate range of plasma exposure levels achieved after oral administration further bolster GT-02287's best and first-in-class potential.

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease

After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher

Gain Therapeutics (GANX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.

News for Gain Therapeutics Stock (GANX)